We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF
IHE

63 hedge funds and large institutions have $157M invested in iShares US Pharmaceuticals ETF in 2013 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 18 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

50% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 18

0% more funds holding

Funds holding: 63 → 63 (0)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 7

5% less capital invested

Capital invested by funds: $164M → $157M (-$7.67M)

12.55% less ownership

Funds ownership: 107.64% → 95.09% (-13%)

Holders
63
Holders Change
–
Holders Change %
0%
% of All Funds
2.04%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
7
Increased
27
Reduced
18
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
RJFSA
Raymond James Financial Services Advisors
Florida
+$4.94M
2
Wells Fargo
Wells Fargo
California
+$1.87M
3
Morgan Stanley
Morgan Stanley
New York
+$838K
4
SG Americas Securities
SG Americas Securities
New York
+$750K
5
Brown Advisory
Brown Advisory
Maryland
+$413K

Top Sellers

1
Fidelity Investments
Fidelity Investments
Massachusetts
-$9.83M
2
CCMG
Clark Capital Management Group
Pennsylvania
-$6.13M
3
Rafferty Asset Management
Rafferty Asset Management
New York
-$5.77M
4
Susquehanna International Group
Susquehanna International Group
Pennsylvania
-$2.72M
5
Bank of America
Bank of America
North Carolina
-$1.84M
Name Holding Trade Value Shares
Change 		Change in
Stake
HSBC Holdings
26
HSBC Holdings
United Kingdom
$692K – – –
ACM
27
Avalon Capital Management
California
$681K -$42.3K -1,200 -6%
WA
28
WESPAC Advisors
California
$649K +$224K +6,375 +53%
VFS
29
VSR Financial Services
Kansas
$623K -$56.4K -1,602 -8%
NES
30
New England Securities
New York
$514K +$104K +2,958 +26%
ICOA
31
Investment Centers of America
North Dakota
$474K +$119K +3,366 +33%
US Bancorp
32
US Bancorp
Minnesota
$457K – – –
CAN
33
Cetera Advisor Networks
California
$437K +$24.3K +690 +6%
WA
34
WFG Advisors
Texas
$414K +$411K +11,661 New
NPC
35
National Planning Corporation
California
$407K +$49.3K +1,401 +14%
Goldman Sachs
36
Goldman Sachs
New York
$405K +$402K +11,412 New
TYCC
37
Texas Yale Capital Corp
Florida
$396K – – –
AMG
38
Asset Management Group
Connecticut
$366K +$364K +10,332 New
BFS
39
Bradley Foster & Sargent
Connecticut
$277K +$275K +7,800 New
William Blair & Company
40
William Blair & Company
Illinois
$276K – – –
Ameriprise
41
Ameriprise
Minnesota
$267K +$84.1K +2,388 +47%
CCM
42
Condor Capital Management
New Jersey
$261K +$2.75K +78 +1%
CS
43
Credit Suisse
Switzerland
$256K -$4.22K -120 -2%
CB
44
Commerce Bank
Missouri
$223K -$52.8K -1,500 -19%
OC
45
Oppenheimer & Co
New York
$212K +$210K +5,964 New
SI
46
Stephens Inc
Arkansas
$201K +$200K +5,670 New
EWM
47
Edge Wealth Management
New York
$163K – – –
LTFS
48
Ladenburg Thalmann Financial Services
Florida
$163K +$26.3K +747 +19%
BRWA
49
B. Riley Wealth Advisors
Florida
$161K +$4.22K +120 +3%
PAS
50
Partnervest Advisory Services
California
$161K +$60.2K +1,710 +61%
1
2
3

IHE Hedge Fund Activity: Q3 2013 in Review

63 of the 3,084 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2013, worth a combined $157M — down 4.7% from $164M a quarter earlier.

Fund positioning in IHE was balanced in Q3 2013: 7 funds opened new positions, 7 closed out, 27 added to existing stakes and 18 trimmed.

The largest buyer was Raymond James Financial Services Advisors, adding an estimated $4.94M. The largest seller was Fidelity Investments, exiting entirely with an estimated $9.83M sold.

  • 63 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2013, unchanged from Q2 2013.
  • Funds reported $157M of iShares US Pharmaceuticals ETF stock for Q3 2013, down 4.7% quarter-over-quarter.
  • 7 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2013 and 7 closed out, a net change of 0 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2013 was Raymond James Financial Services Advisors, an estimated $4.94M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2013 was Fidelity Investments, an estimated $9.83M sold.

Based on aggregated 13F filings for Q3 2013.